Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07759804 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag

Name: A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag — clinical trial record (NCT07759804)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorLiquidia Technologies, Inc.

Started2026-09

View on ClinicalTrials.gov ↗

Liquidia Technologies, Inc.

6 trials monitored

See all monitored trials

Hypertension

1,786 trials monitored

See 77 trials at risk

This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a medicine breathed into the lungs. Everyone who takes part will receive LIQ861. On the first study day, participants will stop taking selexipag and begin taking LIQ861 four times a day using a small handheld dry powder inhaler. The dose may be increased over time based on how well it is tolerated. Participants will take LIQ861 for 16 weeks. The study will also look at whether switching to LIQ861 affects walking distance, a blood marker of heart strain, and symptoms reported by participants.

Trial Details

NCT Number	NCT07759804
Lead Sponsor	Liquidia Technologies, Inc.
Conditions	Pulmonary Arterial Hypertension (PAH)
Enrollment	20 participants
Start Date	2026-09
Primary Completion	2027-05 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-12